UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities

Cancers, 2022-02, Vol.14 (4), p.1003

2022

Volltextzugriff (PDF)

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis

Experimental dermatology, 2024-01, Vol.33 (1), p.e14978-n/a

2024

Volltextzugriff (PDF)

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Cancer, 2018-09, Vol.124 (18), p.3677-3683

2018

Volltextzugriff (PDF)

A Comprehensive Proteomic SWATH-MS Workflow for Profiling Blood Extracellular Vesicles: A New Avenue for Glioma Tumour Surveillance

International journal of molecular sciences, 2020-07, Vol.21 (13), p.4754

2020

Volltextzugriff (PDF)

Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience

Internal medicine journal, 2023-02, Vol.53 (2), p.242-249

2023

Volltextzugriff (PDF)

Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients

International journal of molecular sciences, 2020-07, Vol.21 (14), p.4954

2020

Volltextzugriff (PDF)

Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"

Cancers, 2020-01, Vol.12 (2), p.308

2020

Volltextzugriff (PDF)

Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy

Frontiers in endocrinology (Lausanne), 2020-11, Vol.11, p.576027

2020

Volltextzugriff (PDF)

Hepatocellular carcinoma in the era of immunotherapy

Current problems in cancer, 2018-01, Vol.42 (1), p.40-48

2018

Volltextzugriff (PDF)

Altered presentation of oropharyngeal cancer, a 6‐year review

ANZ journal of surgery, 2021-06, Vol.91 (6), p.1240-1245

2021

Volltextzugriff (PDF)

Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas

Clinical cancer research, 2019-06, Vol.25 (11), p.3366-3373

2019

Volltextzugriff (PDF)

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

European journal of cancer (1990), 2016-09, Vol.65, p.102-108

2016

Volltextzugriff (PDF)

Interobserver and intraobserver variability of RECIST assessment in ovarian cancer

International journal of gynecological cancer, 2022-05, Vol.32 (5), p.656-661

2022

Volltextzugriff (PDF)

Contemporary management of high-grade gliomas

CNS oncology, 2018-01, Vol.7 (1), p.51-65

2018

Volltextzugriff (PDF)

Barriers and potential solutions to international collaboration in neuro‐oncology clinical trials: Challenges from the Australian perspective

Asia-Pacific journal of clinical oncology, 2022-06, Vol.18 (3), p.259-266

2022

Volltextzugriff (PDF)

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

BMJ open, 2022-09, Vol.12 (9), p.e058107

2022

Volltextzugriff (PDF)

'The Reports of My Death Are Greatly Exaggerated'-Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma

Cancers, 2024-05, Vol.16 (10), p.1906

2024

Volltextzugriff (PDF)

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma

International journal of cancer, 2018-01, Vol.142 (1), p.57-65

2018

Volltextzugriff (PDF)

Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma

Asia-Pacific journal of clinical oncology, 2023-08

2023

Volltextzugriff (PDF)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

Cancer medicine (Malden, MA), 2020-07, Vol.9 (13), p.4640-4647

2020

Volltextzugriff (PDF)

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma

Cancer medicine (Malden, MA), 2020-05, Vol.9 (9), p.3023-3032

2020

Volltextzugriff (PDF)

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas

Current neurology and neuroscience reports, 2023-06, Vol.23 (6), p.263-276

2023

Volltextzugriff (PDF)

Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

Translational oncology, 2023-05, Vol.31, p.101638-101638, Article 101638

2023

Volltextzugriff (PDF)

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

Cancer medicine (Malden, MA), 2020-07, Vol.9 (14), p.4918-4928

2020

Volltextzugriff (PDF)

BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience

Frontiers in oncology, 2023-04, Vol.13, p.1154246-1154246

2023

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Englisch
(117)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

A Comprehensive Proteomic SWATH-MS Workflow for Profiling Blood Extracellular Vesicles: A New Avenue for Glioma Tumour Surveillance

Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience

Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients

Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"

Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy

Hepatocellular carcinoma in the era of immunotherapy

Altered presentation of oropharyngeal cancer, a 6‐year review

Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Interobserver and intraobserver variability of RECIST assessment in ovarian cancer

Contemporary management of high-grade gliomas

Barriers and potential solutions to international collaboration in neuro‐oncology clinical trials: Challenges from the Australian perspective

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

'The Reports of My Death Are Greatly Exaggerated'-Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma

Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas

Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience

Suchergebnisse filtern